IL6R and cancer: However, in this study, neither plasma sIL-6R and sgp130 levels nor the ratios of IL-6:sIL-6R and IL-6:sIL-6R:sgp130 complexes showed prognostic significance, suggesting that the IL-6 classical signaling, but not trans-signaling, may be related to anti-tumor immune responses in cancer patients treated with ICIs.